Abstract
We designed a screening system for new anthracyclines totally based on human tumor material. In the first step of the system, the relative cytotoxicity versus doxorubicin of all new compounds is investigated in a panel of human tumor cell lines, well characterized for resistance factors and p53 status. Only a few analogs are selected through this step for further evaluation. The second step is aimed to investigate the therapeutic efficacy and the tolerability of the analog, which is compared to doxorubicin in a series of human tumor xenografts selected for presenting natural or acquired (by known mechanisms) resistance to the parent drug. Cardiotoxicity in mice is also studied. Cellular and molecular pharmacology studies are also considered. The results of a series of disaccharide anthracycline analogs screened by the system are presented. An analog of the series, MEN 10755, was selected for clinical investigation and is currently evaluated in Phase I trials. The ability of human tumor xenografts to predict the clinical efficacy of anthracycline analogs is also discussed.
Current Medicinal Chemistry
Title: Preclinical Evaluation of New Anthracyclines
Volume: 8 Issue: 1
Author(s): G. Pratesi and S. V. Monestiroli
Affiliation:
Abstract: We designed a screening system for new anthracyclines totally based on human tumor material. In the first step of the system, the relative cytotoxicity versus doxorubicin of all new compounds is investigated in a panel of human tumor cell lines, well characterized for resistance factors and p53 status. Only a few analogs are selected through this step for further evaluation. The second step is aimed to investigate the therapeutic efficacy and the tolerability of the analog, which is compared to doxorubicin in a series of human tumor xenografts selected for presenting natural or acquired (by known mechanisms) resistance to the parent drug. Cardiotoxicity in mice is also studied. Cellular and molecular pharmacology studies are also considered. The results of a series of disaccharide anthracycline analogs screened by the system are presented. An analog of the series, MEN 10755, was selected for clinical investigation and is currently evaluated in Phase I trials. The ability of human tumor xenografts to predict the clinical efficacy of anthracycline analogs is also discussed.
Export Options
About this article
Cite this article as:
Pratesi G. and Monestiroli V. S., Preclinical Evaluation of New Anthracyclines, Current Medicinal Chemistry 2001; 8 (1) . https://dx.doi.org/10.2174/0929867013373949
DOI https://dx.doi.org/10.2174/0929867013373949 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phosphorothioate Oligonucleotides: Effectiveness and Toxicity
Current Drug Targets HCN Pacemaker Channels and Pain: A Drug Discovery Perspective
Current Pharmaceutical Design Neutrophil Function in Severe Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews Effects of Statins on Blood Pressure: A Review of the Experimental and Clinical Evidence.
Current Vascular Pharmacology Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Anti-Shock Garments for Obstetric Hemorrhage
Current Women`s Health Reviews L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design The Treatment of Painful Diabetic Neuropathy
Current Diabetes Reviews Molecular Basis of Mineralocorticoid Receptor Action in the Nervous System
CNS & Neurological Disorders - Drug Targets Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry Behavioral Pharmacology of Cannabinoids with a Focus on Preclinical Models for Studying Reinforcing and Dependence-Producing Properties
Current Drug Abuse Reviews Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters <i>Scaphechinus mirabilis</i> Extract Effectively Inhibits the Proliferation of BPH-1 and LNCaP Prostate Epithelial Cells
The Natural Products Journal Monoamino Oxidase A: An Interesting Pharmacological Target for the Development of Multi-Target QSAR
Mini-Reviews in Medicinal Chemistry Development of Proteinase-Activated Receptor 1 Antagonists as Therapeutic Agents for Thrombosis, Restenosis and Inflammatory Diseases
Current Pharmaceutical Design Functions of Third Extracellular Loop and Helix 8 of Family B GPCRs Complexed with RAMPs and Characteristics of their Receptor Trafficking
Current Protein & Peptide Science